Medical Weight Loss for Manhattan, Kansas Residents

Manhattan, Kansas residents get physician-supervised weight loss by telehealth from New Hope Weight Loss: a $119 doctor review, then compounded semaglutide from $166/month or tirzepatide from $233/month.

Physician-supervised GLP-1 programs from $166/month, serving Manhattan through telehealth from our Costa Mesa, California clinic. Doctor review $119. Over 5,400 patients treated.

Follow-up that stays with you in Manhattan: your care does not end at the first visit, Dr. Sharma and our team check in by secure video as you progress, no matter where you are in Kansas. Results vary. Doctor review just $119 (medication separate).

Why Manhattan Residents Choose New Hope Weight Loss

We made New Hope easy to start without making it less serious. A Manhattan patient can go from first visit to a physician-approved plan without insurance paperwork, prior authorizations, or a single drive to an office. The $119 review with Dr. Anjmun Sharma is flat, the medication price is published, and the whole thing happens by telehealth. Low friction to begin, real medicine once you do, the same standard everyone in Kansas gets.

If you are searching for medical weight loss in Manhattan, New Hope Weight Loss treats patients statewide by telehealth from our Costa Mesa, California clinic. Dr. Sharma reviews your history by secure video and, if appropriate, prescribes compounded semaglutide or tirzepatide shipped to you.

Think of our Costa Mesa clinic as your weight-loss provider even though you live in Manhattan, because telehealth delivers the same physician-led program to Kansas without asking you to leave home. We care for patients throughout downtown Manhattan, the university area, and the Flint Hills of Riley County. Your intake, lab review, and dosing are all overseen by a physician, which means real medical supervision behind every package sent to Manhattan.

Patients on the outskirts of Kansas get the same flat pricing, the same physician, and the same fast start as those near the center of Manhattan. The 90-day semaglutide program is $499, which works out to a lower monthly cost than paying month to month for many Manhattan patients. Across both the urban and rural stretches of Kansas, New Hope Weight Loss cares for patients entirely by telehealth from our Costa Mesa, California clinic.

GLP-1 Weight Loss Programs Available

Semaglutide 90-Day Metabolic Reset, from $166/mo

Most Manhattan patients start here. Semaglutide shares its active ingredient with Wegovy and Ozempic, and in branded-drug trials people lost an average of 15 to 17 percent of body weight. Our program runs $499 for 90 days, with Dr. Sharma adjusting your dose each month by telehealth. Results vary, and compounded semaglutide is not FDA-approved or brand-identical.

Tirzepatide, from $233/mo

Tirzepatide works on two hunger pathways at once, GLP-1 and GIP. In trials of the branded drug, qualified patients reached up to 22.5 percent body-weight loss, which is a high-dose figure and not typical. It shares its active ingredient with Mounjaro and Zepbound.

$119 physician review. Medication is billed separately. We accept HSA, FSA, Klarna, and Affirm, with no surcharge for treating you in Manhattan by telehealth.

How Telehealth Works for Manhattan

Step 1: The quiz. Tell us about your health history, current weight, and goals through a quick online intake.

Step 2: The video visit. Dr. Sharma reviews your intake and meets you by secure video, usually within 48 hours, to discuss whether compounded semaglutide or tirzepatide is a fit. Results vary from person to person.

Step 3: Delivery. A state-licensed 503(a) pharmacy ships your medication to your Manhattan address in cold-pack packaging.

Step 4: Follow-ups. You stay in touch by video as you progress.

Frequently Asked Questions, Manhattan

Is New Hope Weight Loss available to Manhattan without a local branch?

Yes, even though we have no branch in Manhattan. Our one physical clinic is in Costa Mesa, California, and we reach Manhattan, Kansas through telehealth. A secure video consult with Dr. Anjmun Sharma is where your medical history is reviewed and your fit for a compounded GLP-1 plan is confirmed.

From Manhattan, can I avoid traveling for appointments?

You can skip travel entirely. The program is built around telehealth, so Manhattan patients meet the doctor online, complete intake digitally, and stay connected by message. If approved, medication ships to your Manhattan home in cold-pack packaging that maintains a safe temperature on the way.

What will Manhattan patients spend on the program?

Expect $119 for the physician visit. Compounded semaglutide is offered from $166 per month or $499 for 90 days, and tirzepatide from $233 per month. The medication is billed separately. HSA, FSA, Klarna, and Affirm are all accepted, with no distance surcharge for Manhattan residents at all.

What areas of Manhattan do you serve?

We serve patients from across Manhattan by telehealth, including downtown Manhattan, the university area, and the Flint Hills of Riley County.

Who qualifies for the program in Manhattan?

Eligibility for Manhattan patients is decided by Dr. Sharma during the medical review, based on your health history, current medications, and goals. The $119 visit is not charged if you are not a candidate, and there is no obligation to continue.

Manhattan Residents, Get Started Today

Doctor review $119. Semaglutide from $166/mo. Tirzepatide from $233/mo. Medication separate.

Start My Journey →

New Hope Weight Loss | clinic at 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342 | Serving Manhattan, Kansas by telehealth. Telehealth availability and eligibility are confirmed during the medical consultation.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by these companies. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality.